At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
wild-type reovirusbiological
Likely dose
wild-type reovirus 250 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (Reolysin®) in Patients With Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating wild-type reovirus for Recurrent Melanoma and Stage IV Melanoma. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This phase II trial is studying the side effects and how well viral therapy works in treating patients with metastatic melanoma. Viral therapy may be able to kill tumor cells without damaging normal cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Melanoma, Stage IV Melanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedApr 2008
Primary CompletionDec 2011
Study CompletionOct 2012
TodayJul 2026
First PostedApr 2, 2008
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2011
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.3 years ago
Interventions
wild-type reovirusbiological
Given IV: Administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.